Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 6/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4868910 | 0.90 | ALDH1A1 (0.48) | CCR5RAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL2528439 | 0.90 | ALDH1A1 (0.40) | CCR5RAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL2526958 | 0.83 | ALDH1A1 (0.41) | RAB9AMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL5285282 | 0.82 | ALOX5 (0.41) | RAB9ANPC1MAPTALDH1A1ATM | |
| SCHEMBL2526914 | 0.81 | TSHR (0.41) | RAB9AMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL2528124 | 0.81 | TSHR (0.49) | RAB9ANPC1MAPTALDH1A1ATM | |
| SCHEMBL2530897 | 0.81 | ALDH1A1 (0.43) | CCR5MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL4874179 | 0.80 | ALDH1A1 (0.42) | RAB9AMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL4877059 | 0.80 | MEN1 (0.39) | MAPTALDH1A1MEN1KMT2AHTT | |
| SCHEMBL4872653 | 0.78 | ALDH1A1 (0.40) | RAB9AMAPTALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132477-A1 | Macrocyclic Compounds Useful as Bace Inhibitors | NOVARTIS AG (CH) | 2008-06-05 | — | — | US | disclosed |
| EP-1851208-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | Novartis AG (CH) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006074950-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132477-A1 | Macrocyclic Compounds Useful as Bace Inhibitors | BACE1, BACE2, APP | CCR5 2413/4885RAB9A 2224/4885NPC1 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.